Patents by Inventor Zunhong Ke

Zunhong Ke has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for treating angiogenic eye disorders using VEGF antagonists
    Patent number: 11944663
    Abstract: The present patent application provides methods for treating patients having angiogenic eye disorder by administering a VEGF antagonist, particularly an VEGF antagonist comprising the amino acid sequence of SEQ ID NO:1 in one or more treatment phases.
    Type: Grant
    Filed: June 18, 2021
    Date of Patent: April 2, 2024
    Assignee: Chengdu Kanghong Biotechnologies Co. Ltd.
    Inventor: Zunhong Ke
  • NOVEL THYROID HORMONE BETA RECEPTOR AGONIST
    Publication number: 20230257367
    Abstract: The present application provides a novel thyroid hormone ß receptor agonist having better activity, selectivity or safety and represented by formula (I), and use thereof in preventing or treating a disease related to the ß receptor agonist. The disease comprises, for example, obesity, hyperlipidemia, hypercholesterolemia, diabetes, the liver disease (fatty liver, NASH, NAFLD, etc.), the cardiovascular disease (atherosclerosis, etc.), the thyroid disease (hypothyroidism, thyroid cancer, etc.), etc.
    Type: Application
    Filed: June 2, 2021
    Publication date: August 17, 2023
    Applicant: Chengdu Kanghong Pharmaceutical Co., Ltd.
    Inventors: Yongguo Yu, Yiqian Wang, Zunhong Ke
  • RECOMBINANT ADENO-ASSOCIATED VIRUS FOR DELIVERY OF KH902 (CONBERCEPT) AND USES THEREOF
    Publication number: 20230057380
    Abstract: Aspects of the disclosure relate to a recombinant adeno-virus encoding an anti-Vascular endothelial cell growth factor (VEGF) agent in a cell or subject (e.g., rAAV2.7m8-KH902). In some embodiments, compositions described herein are useful for treating subjects having diseases associated with angiogenesis or aberrant VEGF activity/signaling.
    Type: Application
    Filed: November 25, 2020
    Publication date: February 23, 2023
    Applicants: University of Massachusetts, Chengdu Kanghong Biotechnology Co. Ltd.
    Inventors: Guangping Gao, Phillip Tai, Claudio Punzo, Zunhong Ke
  • Method For Treating Angiogenic Eye Disorders Using Vegf Antagonists
    Publication number: 20210393738
    Abstract: The present patent application provides methods for treating patients having angiogenic eye disorder by administering a VEGF antagonist, particularly an VEGF antagonist comprising the amino acid sequence of SEQ ID NO:1 in one or more treatment phases.
    Type: Application
    Filed: June 18, 2021
    Publication date: December 23, 2021
    Applicant: Chengdu Kanghong Biotechnologies Co. Ltd.
    Inventor: Zunhong Ke
  • Construction of oncolytic adenovirus recombinant specifically expressing immune modulatory factor GM-CSF in tumor cells and uses thereof
    Patent number: 7951585
    Abstract: The present invention relates to gene therapy for tumors, specifically, it relates to the construction of oncolytic adenovirus recombinant, which specifically expresses immune modulatory factor GM-CSF in tumor cells and uses thereof.
    Type: Grant
    Filed: November 19, 2004
    Date of Patent: May 31, 2011
    Assignee: Chengdu Kanghong Biotechnologies Co., Ltd.
    Inventor: Zunhong Ke
  • Construction of oncolytic adenovirus recombinant specifically expressing immune modulatory factor gm-csf in tumor cells and uses thereof
    Publication number: 20100047208
    Abstract: The present invention relates to gene therapy for tumors, specifically, it relates to the construction of oncolytic adenovirus recombinant, which specifically expresses immune modulatory factor GM-CSF in tumor cells and uses thereof.
    Type: Application
    Filed: November 19, 2004
    Publication date: February 25, 2010
    Applicant: CHENGDU KANGHONG BIOTECHNOLOGIES CO., LTD
    Inventor: Zunhong Ke